BioAxess Pharmaceuticals is launching Probi Digestis® in Greece

Athens (Greece), 23 January 2017

Probi’s patented, clinically-documented probiotic strains will complement BioAxess’s current OTC portfolio with probiotics for addressing Irritable Bowel Syndrome.

BioAxess was established in 2010 by a number of former multinational managers from pharmaceutical companies in Greece. They already have a number of well-known international brands in their portfolio. BioAxess now establishes a new business unit to focus on food and dietary supplements, with special emphasis on medical marketing and probiotics. Pantelis Achilias, Founder and Managing Director of BioAxess stated “BioAxess has searched for the most appropriate and effective range of probiotic solutions for some time. Now we are able to offer a well-documented probiotic solution to our consumers with Irritable Bowel Syndrom and IBS symptoms”. Peter Nählstedt, CEO of Probi, says: “We are pleased to enter a new market in Europe with our Probi Digestis®. Greece is of the same size as Sweden, where we have been very successful. Historically, the Greeks are used to consuming natural probiotics through olives, yoghurt and other fermented food products. We are looking forward to establishing ourselves in the Greek market and becoming one of the market leaders.”


Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: Niklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile: +46 705 38 88 64, e-mail: Pantelis Achilias, Managing Director, BioAxess, tel +30 6947 560338, e-mail:


probi_logo Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. Probi had sales of MSEK 216 in 2015. The Probi share is listed on NASDAQ OMX Stockholm, Small Cap. Probi has about 3,500 shareholders. Read more at